What cultivated meat is and how it is made
Cultivated meat is animal tissue grown from cells in a bioreactor. A developer takes a small cell sample, establishes and banks a cell line, and grows the cells in a nutrient medium until there is enough biomass to harvest. The result is a cell paste or structured tissue used as meat, fat or a blend ingredient.
The production chain has recognisable steps. Cells are collected, screened and banked, expanded in growing tanks, and in many processes induced to differentiate into muscle, fat or connective tissue, sometimes on scaffolds. A 2025 review credits recent advances to cell line engineering, serum-free media, bioreactor design and three-dimensional assembly technologies.
Regulators look closely at the early steps. A 2026 review argues that cell lines and banking systems are critical determinants of safety, quality and reproducibility, and compares regulatory dossiers that show wide variation in cell line qualification and banking practice. Performance metrics such as doubling time, biomass yield and protein content decide whether a line is viable for industrial use.
Cultivated meat production and cost barriers
Cost remains the central obstacle. The 2025 industrialisation review notes that cultured meat has progressed from early cell culture concepts to regulatory approvals and preliminary commercialisation, but that market-wide pricing remains unattainable. Stakeholders interviewed in a United States study name taste and price parity and production at scale among the sector’s main challenges.
Culture media are a major cost driver. Serum-free and defined media aim to replace expensive animal-derived components, and the review lists serum-free strategies among the focus areas in Asia, where China, Japan, South Korea and Singapore concentrate on scaffold-based three-dimensional cultures and bioinks. Media cost, cell density and bioreactor productivity together determine price per kilogram.
Hybrid products offer a near-term route. Cultivated cells can be blended with plant protein, which lowers the cell content per kilogram and helps with structure. Pork fat cell material, for example, appears in the FDA inventory. Developers of hybrids should state the cultivated share clearly on labels, according to the rules of each market.
Protein content is a design target rather than a fixed property. USDA data show raw ground beef at 18.59 grams of protein per 100 grams and coho salmon at about 21 to 22, which are the values cultivated products aim to match. Water content, fat and the share of non-muscle cells all move the nutrition panel of a cultivated product.
Regulation in the United States
FDA describes a voluntary pre-market consultation in which it evaluates the production process and the cultured cell material, including the establishment of cell lines and cell banks, manufacturing controls and all components and inputs. The consultation is not an approval, and it evaluates the firm’s safety conclusion. FDA completed its first consultation on 16 November 2022.
Responsibility is split between agencies. Under an agreement from March 2019, FDA oversees cell collection, cell banks, and cell growth and differentiation, and oversight then transitions to USDA-FSIS for livestock and poultry products, which require inspection and a mark of inspection. FDA regulates seafood and other species outside USDA authority itself, so seafood products follow the FDA route alone.
The FDA inventory lists completed consultations for cultured chicken cell material, pork fat cell material and coho salmon cell material. Chicken appears under files 000001, 000002 and 000039, pork fat under 000008 and salmon under 000005, with FDA responses dated between 2022 and 2025. The inventory publishes submissions, FDA responses and scientific memos.
Commercial sale also needs facility registration and USDA inspection for meat and poultry. A completed consultation therefore marks one step on a longer route, and developers need grants of inspection and labelling approval before products reach consumers. State-level restrictions add another layer, and the industrialisation review mentions political bans and legislation in some regions.
Regulation in Singapore, the EU and elsewhere
Singapore introduced a novel food framework in 2019, and the Singapore Food Agency treats cultured or cell-based meat grown under controlled conditions as a novel food that must be assessed for safety before sale. An expert working group formed in March 2020 advises it. SFA states that misrepresenting cultured meat as conventionally produced meat will not be allowed.
In the European Union, cultured meat is regulated under Regulation 2015/2283, which classifies products from cell or tissue cultures of animals, plants, microbes, fungi or algae as novel foods. Each product needs an EFSA safety assessment and authorisation. The review notes that Europe and the UK prioritise defined media and cell optimisation, with early commercialisation mainly in pet food.
Other regions are developing frameworks. The review reports that Brazilian authorities intend to share responsibility, with ANVISA covering food safety and MAPA production oversight and labelling, and describes Asia as a leading hub. Australia has issued approval for at least one cultivated product, according to the review, which cites approvals in Singapore, the United States and Australia as of mid-2025.
Applications and uses
Cultivated chicken is the most advanced product category in the United States, where the FDA inventory lists several chicken consultations, and in Singapore. Pork fat is used as a flavour and fat component, and salmon represents the seafood side, covered separately on the cultivated seafood page, which sets out the different regulatory route for fish cells.
Hybrid and blended formats are logical. Cultivated cells can complement plant protein in nuggets, sausages and patties, with texture from extruded proteins such as textured pea protein and flavour from cell material. The chicken-specific variant has its own page, cultivated chicken, which covers poultry products and their labelling in more detail.
Related alternatives address the same demand differently. Mycelium-based products offer a fermentation route to whole-cut texture without animal cells, while precision fermented myoglobin supplies meaty flavour proteins. A product team should compare these routes on cost, label wording, regulatory status and consumer acceptance before choosing a platform for a launch.
Allergen and safety status
Safety assessment covers the cells, the process and the inputs. FDA states that it evaluates cell lines, banks, manufacturing controls and components, and the 2026 review of cell lines proposes a risk-based framework because dossiers vary. Allergen risk follows the source animal, so cultivated chicken carries poultry allergen considerations, and fish cell material carries fish allergen considerations.
Culture medium components are a second safety question. Regulators ask for the identity and purity of growth factors, hormones, amino acid sources and scaffold materials, and for residues in the final product. Serum-free media reduce reliance on animal-derived components and simplify the dossier, but they introduce recombinant proteins whose safety also needs assessment.
Genetic stability is a third. Cell lines that are immortalised or engineered need data on stability and the absence of unintended changes over production runs, and cell banking practices underpin that evidence. Buyers and retailers should ask producers for the regulatory file reference, the species and cell line description, and the labelling approved in each market.
Sourcing and supply
Supply is limited to a handful of companies and pilot plants. The industrialisation review lists approvals for GOOD Meat, UPSIDE Foods, Wildtype, Mission Barns and Vow, and describes preliminary commercialisation. Volumes are small, so large-scale procurement is not yet realistic for most buyers, and early supply agreements should be treated as pilots.
A buyer’s questions should cover species and cell line, regulatory status in each market, cell and culture medium inputs, production scale, cell content of the product and labelling. Ask for specifications for protein, fat, moisture and microbiology, and for allergen statements. Request confirmation of inspection arrangements, since meat and poultry products need USDA grants of inspection in the United States.
Plan for change. Approvals, bans and labelling rules are moving quickly, and stakeholders report a funding decline after the boom years. Developers should treat cultivated meat as a premium or hybrid ingredient for now, keep alternative proteins in the roadmap, and monitor regulator announcements in every target market before committing to launch dates.